Paper Details

  1. Home
  2. Paper Details

[SGLT2 inhibitors: A new era for our patients].

Author: HalimiJean-Michel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Drugs called SGLT2 inhibitors have been shown to significantly reduce the risk of kidney failure (by 35-40%) and hospitalization for heart failure (by 30-35%) in patients with or without type 2 diabetes. They are also effective in patients already taking other drugs for kidney and heart problems. While the benefits are significant, there are some side effects, such as genital yeast infections, urinary tract infections, and a rare but serious condition called Fournier's gangrene.
Paper Details　
Original Abstract of the Article :
Since 2015, 10 randomized clinical trials assessed the cardiovascular safety of SGLT2 inhibitors, and then assessed the potential renal and cardiovascular benefits of these drugs (EMPAREG Outcome, CANVAS, DECLARE, DAPA-HF, CREDENCE, EMPEROR-reduced, VERTIS, DAPA-CKD, SCORED, SOLOIST-WHF) in over 88,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.nephro.2020.12.006

データ提供：米国国立医学図書館（NLM）

SGLT2 Inhibitors: A New Era in Diabetes Management

The field of [diabetes management] is constantly evolving, and [SGLT2 inhibitors] have emerged as a promising new class of medications. This review summarizes the results of multiple [randomized clinical trials] that have evaluated the cardiovascular safety, renal benefits, and cardiovascular benefits of SGLT2 inhibitors. The researchers highlight the significant renal and cardiovascular protection offered by these medications, along with their favorable safety profile.

SGLT2 Inhibitors: A Potential Game Changer for Diabetes

The review reveals that SGLT2 inhibitors have been shown to significantly reduce the risk of [end-stage renal disease], [hospitalization for heart failure], and other cardiovascular events. This makes them a valuable addition to the therapeutic options for managing diabetes and cardiovascular disease.

Navigating Diabetes Treatment: A Desert Oasis in Healthcare

This research emphasizes the transformative potential of SGLT2 inhibitors in diabetes management. It underscores their ability to offer both renal and cardiovascular protection, making them a crucial tool for optimizing patient care.

Dr.Camel's Conclusion

This review is like a compass guiding us through the desert of diabetes management, revealing the promise of SGLT2 inhibitors. The research findings highlight the potential of these medications to significantly improve patient outcomes and reshape the future of diabetes care.

Date :
  1. Date Completed 2021-10-28
  2. Date Revised 2021-10-28
Further Info :

Pubmed ID

33773943

DOI: Digital Object Identifier

10.1016/j.nephro.2020.12.006

SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.